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Introduction {#sec1}
============

Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are both pluripotent stem cells, self-renewing indefinitely *in vitro* and differentiating into all cell types of an organism ([@bib12], [@bib15], [@bib58]). Thus, they have provided new prospects for basic research and regenerative medicine ([@bib4], [@bib8]). The unique properties of ESC/iPSCs are controlled by multiple regulatory mechanisms ([@bib20], [@bib47]). First, OCT4, SOX2, and NANOG are core transcription factors for the establishment and maintenance of pluripotency ([@bib46]). Recently, more transcriptional factors have been shown to involve in the regulation of ESC self-renewal ([@bib14], [@bib26], [@bib46]). Second, leukemia inhibitor factor, together with bone morphogenetic protein 4 or serum, can maintain mouse ESC self-renewal, whereas fibroblast growth factor (FGF)/ERK1/2 signaling and calcineurin-nuclear factor of activated T cells (NFAT) pathways are both essential and sufficient to induce ESC differentiation and early mouse embryonic development ([@bib24], [@bib29], [@bib37]). Additionally, accumulating lines of evidence have indicated that epigenetic modulators also play critical roles in the ESC fate control ([@bib38]). To fulfill the full potential of ESCs, it is necessary to elucidate how these regulatory mechanisms are precisely orchestrated to safeguard ESCs at an undifferentiated state. The interplay between transcriptional factors and epigenetic regulators in ESCs has been intensively investigated ([@bib1], [@bib10], [@bib14], [@bib22], [@bib41]). However, how epigenetic regulators have crosstalks with signaling pathways is poorly understood.

Epigenetic regulation, mediated by DNA/RNA modifications, histone modifications/variants, and non-coding RNAs, provides ESCs with a unique chromatin conformation, allowing for the activation of pluripotency genes and the suppression of developmental genes ([@bib2], [@bib67]). Histone modifications are the important part of epigenetics and play critical roles in the regulation of ESC identity ([@bib34]). Generally H3K4 methylation correlates with gene activation, while H3K27 and H3K9 methylation are associated with gene repression ([@bib28]). The Trithorax group (*trxG*)-mediated H3K4 methylation and the Polycomb group (*PcG*)-mediated H3K27 methylation have been widely investigated in the maintenance and establishment of the pluripotent state ([@bib19], [@bib34], [@bib38]). In contrast, the distribution and functions of H3K9 methylation are more complicated and less studied in ESCs and somatic cell reprogramming. It has been reported that H3K9 dimethylation (H3K9me2) has a broad distribution and covers more than one-third of the genome ([@bib40]). Interestingly, H3K9me2 is maintained at a low level in ESCs and undergoes drastic changes during ESC differentiation ([@bib65]), indicating a key role of H3K9 demethylases in the maintenance of ESC identity.

H3K9 demethylation is mainly catalyzed by Fe(II)- and α-ketoglutarate-dependent JmjC-domain-containing proteins, including the JMJD1/KDM3 family, JMJD2/KDM4 family, and PHF8/KDM7B ([@bib44], [@bib50]). In addition, flavin adenine dinucleotide (FAD)-dependent amine oxidase LSD1/KDM1A has also been demonstrated to remove H3K9me1/2 ([@bib32], [@bib44]). Among these H3K9 demethylases, a few have been shown to be required for the maintenance of ESC identity, including JMJD1A, JMJD2B, and JMJD2C ([@bib11], [@bib41]). Besides, the regulatory mechanisms underlying the role of the three H3K9 demethylases in ESCs are not fully addressed, particularly from the perspective of interaction between histone modifications and signaling pathways. Hence, we asked whether there would be other H3K9 demethylases required for the induction and maintenance of pluripotency, and if so, how the function is executed.

In this study, to address the above questions we performed a functional RNAi screen against H3K9 demethylases in mouse ESCs and found that JMJD1C is required for ESC self-renewal and efficient somatic cell reprogramming. Mechanistically, JMJD1C could antagonize the ERK/MAPK pathway and the epithelial-to-mesenchymal transition (EMT) process to maintain ESCs in the undifferentiated state. Moreover, our results reveal a direct regulatory role of JMJD1C and pluripotency factor KLF4 for the expression of the *miR-200* family and *miR-290*/*295* cluster, which is, at least in part, responsible for JMJD1C\'s function in ESCs. Therefore, this study reports an important function of JMJD1C, revealing a crosstalk between an epigenetic regulator and one of the key signaling pathways in ESC fate determination.

Results {#sec2}
=======

JMJD1C Is Required for the Maintenance of ESC Self-Renewal {#sec2.1}
----------------------------------------------------------

We began with comparing the expression level of various H3K9 demethylases between mouse ESCs and mouse embryonic fibroblasts (MEFs) and found substantially higher transcript levels of most examined H3K9 demethylases in ESCs than in MEFs ([Figure S1](#mmc1){ref-type="supplementary-material"}A), suggesting their potential association with the ESC state. To find H3K9 demethylases required for the maintenance of ESC identity, we performed a small-scale functional RNAi screen against H3K9 demethylases ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and found that, in addition to JMJD1A and JMJD2C ([@bib11], [@bib41]), JMJD1B and JMJD1C were also required to sustain ESCs in the undifferentiated state ([Figure S1](#mmc1){ref-type="supplementary-material"}C). In contrast, knockdown (KD) of *Jmjd2a*, *Jmjd2b*, *Jmjd2d*, or *Phf8* did not change the ESC morphology markedly. JMJD1C was previously identified to associate with OCT4, NANOG, TFCP2L1, and ESRRB ([@bib10], [@bib13], [@bib61]). Moreover, our real-time qRT-PCR results showed that *Jmjd1c* was highly expressed in undifferentiated ESCs and downregulated during embryoid body (EB) formation, paralleling with levels of *Oct4* and *Nanog* ([Figure 1](#fig1){ref-type="fig"}A). However, its role in regulating mouse ESC self-renewal is as yet unreported. Therefore, we decided to focus on *Jmjd1c* in the subsequent study.Figure 1JMJD1C Is Required for ESC Self-Renewal(A) qRT-PCR analysis of *Jmjd1c*, *Oct4*, and *Nanog* expression levels during embryoid body (EB) formation. Data are presented as mean ± SD of three independent experiments.(B) Bright-field images and alkaline phosphatase (AP) staining of ESCs after *Jmjd1c* knockdown (KD) for 4 days. See also [Figure S1](#mmc1){ref-type="supplementary-material"}E.(C) qRT-PCR analysis of pluripotency and primordial germ cell (PGC) gene expression after 4 days of *Jmjd1c* KD. Data are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(D) Western blot analysis of JMJD1C, OCT4, SOX2, and KLF4 after 4 days of *Jmjd1c* KD. α-TUBULIN was used as a loading control. See also [Figure S1](#mmc1){ref-type="supplementary-material"}F.(E) qRT-PCR analysis of lineage-specific gene expression after 4 days of *Jmjd1c* KD. Data are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(F and G) Colony-formation assays for *Jmjd1c* KD (sh*Jmjd1c*\#3, sh*Jmjd1c*\#4) and control (shNT) ESCs (F) and their quantification (G). Data are presented as mean ± SD of four independent experiments. ^∗∗∗^p \< 0.001.(H and I) Schematic illustration (H) and results (I) of competition assays for mixed populations of *Jmjd1c* KD and control ESCs. Data are presented as mean ± SD of three independent experiments.

To silence *Jmjd1c* expression efficiently and specifically, we designed four short hairpin RNAs (shRNAs) targeting its mRNA sequences and found that sh*Jmjd1c*\#3 and sh*Jmjd1c*\#4 had higher efficiencies to KD *Jmjd1c* expression than the other two shRNAs ([Figure S1](#mmc1){ref-type="supplementary-material"}D). *Jmjd1c* KD resulted in the loss of typical ESC morphology and alkaline phosphatase (AP) activities, while transfection of ESCs with non-target control shRNA (shNT) did not have such effects ([Figure 1](#fig1){ref-type="fig"}B). Similar results were obtained in another ESC line, CGR8 ([Figure S1](#mmc1){ref-type="supplementary-material"}E). In addition, *Jmjd1c* KD led to significantly decreased expression levels of pluripotency genes (*Oct4*, *Sox2*, *Nanog*, *Klf2*, *Klf4*, *Klf5*, *Esrrb*, *Nr5a2*, *Tbx3*, *Tcl1*, and *Tfcp2l1*) ([Figures 1](#fig1){ref-type="fig"}C, 1D, and [S1](#mmc1){ref-type="supplementary-material"}F) and increased levels of lineage markers, including those of the endoderm (*Bmp2*, *Dab2*, and *Gata4*), the mesoderm (*T*, *Bmp4*, and *Isl1*), the ectoderm (*Fgf5*, *Nestin*, *Pax6*, and *Cxcl12*), and the trophectoderm (*Cdx2* and *Eomes*) ([Figure 1](#fig1){ref-type="fig"}E). Primordial germ cell markers such as *Stella* (*Dppa3*), *Prdm1*, and *Tcfap2c* also were downregulated in *Jmjd1c* KD ESCs ([Figure 1](#fig1){ref-type="fig"}C), verifying the previous report that JMJD1C is required for the long-term maintenance of mouse male germ cells ([@bib30]). To validate that JMJD1C was indeed required for ESC self-renewal, we performed ESC colony formation and competition assays and found that *Jmjd1c* KD drastically reduced the capacity of ESCs to self-renew, as evidenced by reduced undifferentiated ESC colony numbers and percentages of sh*Jmjd1c*-transfected GFP^+^ cells ([Figures 1](#fig1){ref-type="fig"}F--1I). Taken together, our results reveal that JMJD1C is required for the maintenance of ESC self-renewal.

Silencing of *Jmjd1c* Activates ERK/MAPK Signaling and the Epithelial-to-Mesenchymal Transition {#sec2.2}
-----------------------------------------------------------------------------------------------

Given that JMJD1C is known as an H3K9 demethylase responsible for the removal of H3K9me1/2 ([@bib7], [@bib27]), we reasoned that JMJD1C might regulate gene expression through removing H3K9 methylation. We therefore examined the global H3K9 methylation level. As anticipated, *Jmjd1c* KD resulted in increased levels of H3K9 methylation, including H3K9me1, H3K9me2, and H3K9me3 ([Figure 2](#fig2){ref-type="fig"}A). To understand how *Jmjd1c* KD and resultant changes in H3K9 methylation would affect ESCs at a global gene expression level, we compared the whole-genome transcriptomes between the control and *Jmjd1c* KD ESCs (6 samples, including 2 shNT control samples and 4 sh*Jmjd1c* samples, 2 from \#3 and 2 from \#4 shRNA, respectively; [Figure 2](#fig2){ref-type="fig"}B) and identified 540 upregulated and 321 downregulated genes, respectively. Gene ontology (GO) analysis of these differentially expressed genes (DEGs) showed that the top GO terms were associated with cell differentiation and the EMT process ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}A). Signaling pathway analysis indicated that these DEGs were enriched in the terms of focal adhesion, extracellular matrix-receptor interaction, MAPK signaling, and RAS signaling ([Figures 2](#fig2){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}B). As the activated MAPK signaling and EMT have been demonstrated to be key events for mouse ESCs to exit from the self-renewal state ([@bib29], [@bib37]), we first examined the phosphorylated ERK1/2 levels and found that *Jmjd1c* KD activated ERK1/2 signaling ([Figure 2](#fig2){ref-type="fig"}E). Next, we examined EMT markers in *Jmjd1c* KD cells and found that depletion of *Jmjd1c* led to the downregulation of epithelial markers, including *Cdh1* (*E-cadherin*), *Epcam*, *Cldn3*, *Crb3*, and *Ocln* ([Figure 2](#fig2){ref-type="fig"}F), and the upregulation of mesenchymal markers, including *Cdh2* (*N-cadherin*), *Zeb2*, *Twist2*, and *Mmp9* ([Figure 2](#fig2){ref-type="fig"}G). These data suggest that JMJD1C may function to suppress the activation of ERK/MAPK signaling and EMT process in undifferentiated ESCs.Figure 2Knockdown of *Jmjd1c* Activates the ERK/MAPK Signaling and EMT in ESCs(A) Representative western blot analysis of global H3K9 methylation levels after 4 days of *Jmjd1c* KD in CGR8 and J1 ESC lines. Histone H3 and α-TUBULIN were used as loading controls.(B) Hierarchical clustering of differentially expressed genes (DEGs) (fold changes \>1.5) from *Jmjd1c* KD (sh*Jmjd1c*\#3, sh*Jmjd1c*\#4) and control (shNT) ESCs. Data from two independent experiments are shown.(C) Biological process GO enrichments of DEGs (fold changes \>1.5). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.(D) Signaling pathway analysis of DEGs (fold changes \>1.5). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.(E) Representative western blot analysis of ERK1/2 and phospho-ERK1/2 after 4 days of *Jmjd1c* KD. α-TUBULIN was used as a loading control.(F and G) qRT-PCR analysis of transcript levels for markers of the epithelial-to-mesenchymal transition (EMT) process after 4 days of *Jmjd1c* KD. Data are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Inhibition of ERK/MAPK Signaling Abolishes ESC Differentiation Induced by *Jmjd1c* Depletion {#sec2.3}
--------------------------------------------------------------------------------------------

To answer the question of whether activated ERK/MAPK signaling process could be the cause of ESC differentiation induced by *Jmjd1c* KD, we tested whether inhibition of the pathway could rescue *Jmjd1c* KD-induced phenotypes. Strikingly, sh*Jmjd1c*-treated ESCs exhibited largely normal compacted colonies in the presence of a MEK1/2 inhibitor PD0325901, whereas the same cells displayed an extensively differentiated morphology in the absence of the inhibitor ([Figure 3](#fig3){ref-type="fig"}A). Moreover, treatment of *Jmjd1c* KD cells with the inhibitor restored the pluripotency gene expression almost to normal levels ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A) and attenuated the upregulation of lineage markers ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}B). The inhibition of ERK/MAPK signaling also suppressed the EMT process, as shown by restoring *Jmjd1c* deficiency-caused alterations in the expression levels of epithelial and mesenchymal markers ([Figures 3](#fig3){ref-type="fig"}D, 3E, [S3](#mmc1){ref-type="supplementary-material"}C, and S3D). The latter finding is consistent with our previous finding that the enhanced EMT was downstream of the activated ERK/MAPK signaling ([@bib37]). Additionally, matrix metalloproteinases (MMPs) are key components of the EMT, and the broad-spectrum MPP inhibitor GM6001 is known to prevent the EMT process ([@bib3], [@bib59]). We therefore treated the control and *Jmjd1c*-deficient cells with GM6001 and found that the inhibitor rescued the differentiation phenotypes partially, being less efficient than the ERK/MAPK inhibitor in terms of both cell morphology ([Figure 3](#fig3){ref-type="fig"}F) and expression levels of epithelial and mesenchymal markers ([Figures 3](#fig3){ref-type="fig"}G, 3H, [S3](#mmc1){ref-type="supplementary-material"}E, and S3F). Collectively, these results indicate that JMJD1C suppresses ERK/MAPK signaling and the EMT process to maintain ESC identity.Figure 3Inhibition of ERK/MAPK Signaling or EMT Rescues the Differentiation Phenotype Caused by *Jmjd1c* Depletion(A) Bright-field images of *Jmjd1c*-depleted and control ESCs after treatment with DMSO or the MEK1/2 inhibitor PD0325901 (1 μM) for 4 days.(B and C) qRT-PCR analysis of transcript levels for pluripotency (B) and lineage (C) genes in *Jmjd1c*-depleted and control ESCs after treatment with DMSO or the MEK1/2 inhibitor PD0325901 (1 μM) for 4 days. Data are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; ns, not significant.(D and E) Expression levels of EMT markers in *Jmjd1c*-depleted and control ESCs after treatment with DMSO or the MEK1/2 inhibitor PD0325901 (1 μM) for 4 days. Data are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; ns, not significant.(F) Bright-field images of *Jmjd1c*-depleted and control ESCs after treatment with DMSO or the MMPs inhibitor GM6001 (50 μM) for 4 days.(G and H) Expression levels for EMT markers in *Jmjd1c*-depleted and control ESCs after treatment with DMSO or the MMPs inhibitor GM6001 (50 μM) for 4 days. Data are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; ns, not significant.

The *miR-200* Family and *miR-290*/*295* Cluster Are Key Downstream Targets of JMJD1C {#sec2.4}
-------------------------------------------------------------------------------------

The next question we asked was how JMJD1C suppressed the ERK/MAPK signaling and EMT process in ESCs. Given that JMJD1C acts to reduce the levels of H3K9me1/2, repressive marks for gene expression ([@bib7], [@bib27]), we hypothesized that JMJD1C might suppress the ERK/MAPK signaling and EMT process in an indirect manner. MicroRNAs generally play inhibitory roles in regulating gene expression at a post-transcriptional and/or translational level ([@bib42]). We inferred that JMJD1C might antagonize the ERK/MAPK signaling and EMT process through controlling microRNA expression. To test this deduction, we examined whether expression levels of microRNAs highly expressed in pluripotent stem cells, including *miR-290*/*295*, *miR-302*/*367*, *miR-17*/*92*, *miR-106a*/*363*, *miR-106b*/*25*, *miR-200b*/*429*, *miR-200c*/*141*, and *miR-183*/*182* ([@bib18]), could be regulated by JMJD1C. As each microRNA cluster is composed of several microRNAs, we first examined primary transcripts of these microRNA clusters in *Jmjd1c* KD cells. Clusters of *miR-183*/*182*, *miR-106b*/*25*, *miR-200b*/*429*, *miR-200c*/*141*, and *miR-290*/*295* were downregulated significantly by *Jmjd1c* KD, while there were no significant differences for clusters of *miR-17*/*92*, *miR-106a*/*363*, and *miR-302*/*367* between control and *Jmjd1c* KD cells ([Figure 4](#fig4){ref-type="fig"}A). We then examined the mature microRNAs of clusters controlled by JMJD1C. Notably, all members of these clusters examined had significantly lower levels in *Jmjd1c* KD cells than in control cells ([Figure 4](#fig4){ref-type="fig"}B), suggesting an important role of JMJD1C for maintaining the expression of these microRNAs. To provide evidence for the direct regulation of these microRNA expressions, we conducted chromatin immunoprecipitation (ChIP)-qPCR assays using affinity-purified rabbit polyclonal JMJD1C antibodies made in our laboratory and ChIP-grade hemagglutinin (HA) antibodies in ESCs where an FLAG-HA tag was knocked into the C terminus of the endogenous *Jmjd1c* locus by the CRISPR/Cas9 system ([Figure S4](#mmc1){ref-type="supplementary-material"}A), respectively. With multiple primers against promoter regions of *miR-200b*/*429* cluster, *miR-200c*/*141* cluster, and *miR-290*/*295* cluster, we detected relatively high enrichments of JMJD1C at P1--P5 regions of the *miR-200b*/*429* cluster, at P5--P8 regions of the *miR-200c*/*141* cluster, at P1--P4 and P6--P8 regions of the *miR-290*/*295* cluster ([Figures 4](#fig4){ref-type="fig"}C and 4D). In addition, we found JMJD1C enrichments at enhancer and promoter regions of *Oct4* ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Specifically, these JMJD1C enrichments were significantly reduced when *Jmjd1c* expression was silenced ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D, compared with data in [Figures S4](#mmc1){ref-type="supplementary-material"}B and [4](#fig4){ref-type="fig"}D). Furthermore, we found that JMJD1C bound to the promoter regions of *Klf4*, an important ESC self-renewal-associated gene, particularly at P4--P7 regions ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F). Thus, JMJD1C might directly activate the expression of *miR-200b*/*429*, *miR-200c*/*141*, and *miR-290*/*295* clusters and pluripotency factors (*Oct4* and *Klf4*) to maintain ESC identity.Figure 4JMJD1C and KLF4 Directly Regulate Expression of *miR-200* Family and *miR-290*/*295* Cluster to Sustain ESC Identity(A) qRT-PCR analysis of primary transcripts of microRNA clusters after 4 days of *Jmjd1c* KD. Data are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01.(B) qRT-PCR analysis of mature transcripts of microRNA clusters after 4 days of *Jmjd1c* KD. Data are presented as mean ± SD of four independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(C) Schematic illustration showing the location of amplicons used to evaluate ChIP-enriched genomic regions and transcription factor binding sites at loci of *miR-200* family and *miR-290*/*295* cluster.(D) ChIP-qPCR assays using JMJD1C and HA antibodies in *Jmjd1c*^FLAG-HA^ ESCs. Relative fold enrichments are shown. The value from control immunoglobulin G (IgG) ChIP-qPCR under the same condition was set as 1. Data are presented as mean ± SD of four independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(E) Bright-field images of control and *Jmjd1c*-depleted ESCs after 4 days of transfection with negative control (NC), microRNA mimics, or microRNA mutants. Mut4n and mut7n are mutants of *miR-200* family, harboring 4- and 7-base mutations, respectively, in the seed region.(F) ChIP-qPCR assays using KLF4 antibodies in *Jmjd1c*^FLAG-HA^ ESCs. Relative fold enrichments are shown. The value from control IgG ChIP-qPCR under the same condition was set as 1. Data are presented as mean ± SD of three independent experiments; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(G) Western blot analysis of KLF4 and JMJD1C^FLAG-HA^ after 3 days of *Klf4* KD. α-TUBULIN was used as a loading control.(H) ChIP-qPCR assays using HA antibodies in control and *Klf4*-depleted *Jmjd1c*^FLAG-HA^ ESCs. Relative fold enrichments were normalized to HA ChIP-qPCR in control *Jmjd1c*^FLAG-HA^ ESCs under the same condition. Data are presented as mean ± SD of three independent experiments ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

To determine the causative link between *Jmjd1c* KD-induced ESC differentiation and altered expression levels of JMJD1C-regulated microRNAs and pluripotency factors, we examined their expression levels at 24 hr post infection of the *Jmjd1c* shRNA virus. As a result, we found that primary transcripts of *miR-200* family and *miR-290-295* cluster as well as *Klf4* mRNA levels were downregulated at this early time point after *Jmjd1c* KD, while the expression levels of most lineage markers did not change ([Figure S4](#mmc1){ref-type="supplementary-material"}G), suggesting that these microRNAs and *Klf4* might be important downstream targets of JMJD1C. To test this assumption at a functional level, we overexpressed mimics of these microRNAs in *Jmjd1c*-deficient ESCs. Notably, *miR-200*s and *miR-295*, rather than their mutants, largely rescued the differentiation phenotype caused by *Jmjd1c* KD ([Figures 4](#fig4){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}H--S4J). Thus, the *miR-200* family and *miR-290*/*295* cluster could be key effectors for JMJD1C to maintain ESCs at the undifferentiated state.

We finally asked how JMJD1C was localized to its target genes. It has been reported that JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors ([@bib7]). We therefore analyzed the genomic regions specifically enriched for JMJD1C and predicted the transcription factor binding motifs by DIANA-miRGen v3.0 ([@bib17]). Specific DNA binding motifs of TFCP2L1, OCT4/SOX2, ESRRB, KLF4, and FOXP1 were found ([Figure 4](#fig4){ref-type="fig"}C). Among these factors, KLF4 binding motifs were present at promoters of both *miR-200* family and *miR-290*/*295* cluster. We conducted KLF4 ChIP-qPCR assays and validated the enrichment of KLF4 at these regions ([Figure 4](#fig4){ref-type="fig"}F). Importantly, *Klf4* KD, without reducing JMJD1C protein levels, led to reduced JMJD1C binding to these microRNA loci ([Figures 4](#fig4){ref-type="fig"}G and 4H) and the downregulation of *miR-200* family and *miR-290*/*295* cluster ([Figure S4](#mmc1){ref-type="supplementary-material"}K). Furthermore, we found protein interactions between endogenous KLF4 and JMJD1C in ESCs ([Figure S4](#mmc1){ref-type="supplementary-material"}L). Altogether, these results lead to our conclusion that KLF4 recruits JMJD1C to the promoters of *miR-200* family and *miR-290*/*295* cluster to activate their expression.

JMJD1C Suppresses the ERK/MAPK Signaling and EMT through Controlling *miR-200* Family and *miR-290*/*295* Cluster Expression {#sec2.5}
----------------------------------------------------------------------------------------------------------------------------

To identify genes targeted by the *miR-200* family and *miR-290*/*295* cluster, we predicted their targets using TargetScan (Mouse 7.1) ([@bib35]) and overlapped these predicted targets with *Jmjd1c* KD-upregulated DEGs detected by our microarray analysis ([Figures 2](#fig2){ref-type="fig"}B, [5](#fig5){ref-type="fig"}A, and 5B), uncovering 93 and 42 potential targets of *miR-200* family and *miR-290*/*295* cluster, respectively ([Table S1](#mmc1){ref-type="supplementary-material"}). Among these potential targets, there were components of ERK/MAPK signaling, including integrin β-8 (*Itgb8*), insulin growth factor 2 (*Igf2*), *c-Jun*, *Ets1*, *Tgfb2*, and *Tgfbr2* ([@bib21], [@bib51], [@bib56]), as well as EMT inducers, including *Zeb2*, *Lats2*, *c-Jun*, *Ets1*, *Tgfb2*, *Tgfbr2*, and *Igf2* ([@bib31], [@bib39], [@bib53], [@bib66]). To narrow down and find true functional targets, we then examined their expression patterns in control and *Jmjd1c* KD cells transfected with mimics of *miR-200* family and *miR-290*/*295* cluster, respectively. Overexpression of *miR-200*s or *miR-295*, in particular microRNAs sharing an AAUACUG seed sequence (*miR-429*, *miR-200b* and *miR-200c*), abrogated the upregulation of these identified genes in *Jmjd1c* KD cells ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}A). In addition, *miR-200*s or *miR-295* diminished the downregulation of epithelial markers and upregulation of mesenchymal markers caused by *Jmjd1c* KD ([Figures 5](#fig5){ref-type="fig"}D, 5E, [S5](#mmc1){ref-type="supplementary-material"}B, and S5C). Mutations of these microRNAs in the seed sequence led to the loss of their ability to rescue *Jmjd1c* KD-mediated aberrant expression of these marker genes ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C), demonstrating the function specificity of the microRNAs. Notably, *miR-200*s could reverse the increased pERK1/2 level caused by *Jmjd1c* KD ([Figure 5](#fig5){ref-type="fig"}F). Collectively, these results support the notion that JMJD1C suppresses the ERK/MAPK signaling and the EMT process, at least in part, through controlling *miR-200* family and *miR-290*/*295* cluster expression.Figure 5*miR-200* Family and *miR-290*/*295* Cluster Maintain ESC Identity through Suppressing ERK/MAPK Signaling and EMT Process(A and B) Venn diagrams of overlapping genes between predicted microRNA targets (*miR-200s* \[A\] and *miR-295* \[B\]) by TargetScan and *Jmjd1c* KD-caused upregulated genes (DEGs) detected by KD microarray analysis.(C) qRT-PCR analysis of key targets of *miR-200*s and *miR-295* in control and *Jmjd1c*-depleted ESCs 4 days post transfection with NC or microRNA mimics. Data are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(D and E) qRT-PCR analysis of EMT markers in control and *Jmjd1c*-depleted ESCs 4 days post transfection with NC or microRNA mimics. Data are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(F) Representative western blot analysis of ERK1/2 and phospho-ERK1/2 in control and *Jmjd1c*-depleted ESCs 3 days post transfection with NC or *miR-200*s (*miR-200a*, *miR-200b*, and *miR-200c*). α-TUBULIN was used as a loading control.

JMJD1C Ensures Efficient Somatic Cell Reprogramming {#sec2.6}
---------------------------------------------------

We next tested the role of JMJD1C in the re-establishment of pluripotency from MEFs mediated by Yamanaka factors (OCT4, SOX2, KLF4 and C-MYC, OSKM). First, *Jmjd1c* expression was gradually upregulated during MEF reprogramming, in parallel with the upregulation of *Nanog* and *Esrrb* ([Figure 6](#fig6){ref-type="fig"}A). Second, when *Jmjd1c* was depleted by its specific shRNA in MEFs carrying a transgenic *Oct4* promoter-driven *GFP* cassette, the number of OCT4-GFP-positive colonies decreased significantly, with approximately 40% of that in control cells ([Figure 6](#fig6){ref-type="fig"}B). To further validate the role of JMJD1C, we derived *Jmjd1c*^+/+^ (wild-type \[WT\]), *Jmjd1c*^+/−^ (heterogeneous \[HET\]), and *Jmjd1c*^−/−^ (knockout \[KO\]) MEFs from corresponding mouse embryos and reprogrammed these MEFs to iPSCs. Strikingly, *Jmjd1c* KO almost abolished the ability of MEFs to reprogram, as indicated by AP staining results at reprogramming day 14 ([Figures 6](#fig6){ref-type="fig"}C and 6D). Intriguingly, *Jmjd1c* HET MEFs also displayed a significantly reduction in the AP-positive colony number. To determine whether overexpression of *miR-200* family could rescue the defect of *Jmjd1c*-null MEFs in reprogramming, we infected *Jmjd1c* WT and *Jmjd1c*-null MEFs with retroviruses carrying sequences for the *OSKM* and *miR-200*s to generate iPSCs. Our results showed that *miR-200*s could restore the reprogramming efficiency of *Jmjd1c*-null MEFs to levels comparable with that of *Jmjd1c* HET MEFs ([Figures 6](#fig6){ref-type="fig"}C and 6D). Although *miR-200b* could enhance the reprogramming efficiency in both KO and WT MEFs, the effect was more robust in KO MEFs than in WT MEFs ([Figures 6](#fig6){ref-type="fig"}C and 6D). Therefore, it is likely that JMJD1C ensures efficient somatic cell reprogramming, partially if not mostly, by regulating microRNA expression.Figure 6JMJD1C Is Indispensable for Efficient Somatic Cell Reprogramming(A) qRT-PCR analysis of *Jmjd1c*, *Nanog*, and *Esrrb* expression levels during MEF reprogramming. Data are presented as mean ± SD of three independent experiments.(B) Analysis of GFP^+^ colonies generated from control (sh*Luc*) and *Jmjd1c*-depleted (sh*Jmjd1c*) *Oct4-GFP* MEFs. Data are presented as mean ± SD of three independent experiments. ^∗∗^p \< 0.01.(C and D) Analysis of AP colonies generated from *Jmjd1c* wild-type (WT), heterogeneous (HET), and knockout (KO) MEFs, as well as WT and KO MEFs ectopically overexpressing *miR-200*s. Data in (D) are presented as mean ± SD of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(E) RT-PCR analysis of the activation of endogenous (Endo) pluripotency genes and silencing of exogenously introduced (Retro) pluripotency genes in *Jmjd1c* WT and KO iPSCs. *Gapdh* was used as an internal control.(F) A proposed working model of JMJD1C in mouse ESCs and for somatic cell reprogramming. JMJD1C is recruited to the regulatory regions of subsets of pluripotency genes and microRNAs (targets) with the help of KLF4 to activate their transcription. Members of the *miR-200* family and *miR-290*/*295* cluster suppress the ERK/MAPK signaling and EMT process. In addition, JMJD1C ensures efficient induction of pluripotency partially via microRNA expression.

Finally, we evaluated the role of JMJD1C in the derivation and maintenance of iPSC lines. We found that WT iPSCs showed the typical morphology of ESCs and were expandable, while KO iPSCs tended to differentiate and died gradually after several passages, suggesting that JMJD1C was required for the maintenance of iPSC identity. Furthermore, endogenous pluripotency genes and exogenously introduced pluripotency genes were efficiently activated and silenced, respectively, in WT iPSCs ([Figure 6](#fig6){ref-type="fig"}E). In contrast, exogenously introduced pluripotency genes were not fully silenced and endogenous pluripotency genes were not robustly activated in *Jmjd1c* KO iPSCs, indicative of partial reprogramming ([Figure 6](#fig6){ref-type="fig"}E). This observation points out that JMJD1C is indispensable for bona fide induction of pluripotency from somatic cells.

Discussion {#sec3}
==========

ESCs have a more open and transcriptionally permissive chromatin state than differentiated cells ([@bib43]). Methylation of the repressive marker H3K9 is maintained at a low level in ESCs ([@bib40]). Some H3K9 demethylases have been indicated to be required for the maintenance of ESC identity ([@bib11], [@bib41]). [@bib41] showed that JMJD1A and JMJD2C maintain ESC self-renewal via the regulation of *Tcl1* and *Nanog* expression, respectively. Recently, [@bib11] proposed that JMJD2B and JMJD2C play distinct and combinational functions in the maintenance of mouse ESC identity. Their studies propose that JMJD2B and NANOG act through an interconnected regulatory loop, while JMJD2C assists PRC2 in transcriptional repression. More recently, [@bib49] revealed that JMJD2A and JMJD2C have redundant roles in mouse ESCs, and their simultaneous loss impairs ESC proliferation and induces ESC differentiation into primitive endoderm. These studies reveal the existence of distinct functions and complicated regulatory mechanisms for H3K9 demethylases.

Here, we report an essential role of JMJD1C, a member of the JMJD1/KDM3 demethylase family, for the maintenance of ESC self-renewal. Distinctly from previously reported roles of the JMJD2/KDM4 family H3K9 demethylases, JMJD1C cooperates with pluripotency transcription factor KLF4 to promote the expression of the *miR-200* family and *miR-290*/*295* cluster to suppress the ERK/MAPK signaling and EMT process, ensuring ESC self-renewal. In addition, we identify subsets of genes potentially responsible for JMJD1C-microRNA-mediated function in ESCs. These include genes associated with the ERK/MAPK signaling and EMT process. Thus, we establish a previously unrecognized JMJD1C/KLF4-microRNA-ERK/MAPK axis, providing important insights into the crosstalk between the epigenetic regulator and signaling in controlling ESC fate.

It has been recently demonstrated that H3K9 methylation is a barrier for reprogramming somatic cell into iPSCs ([@bib6]). Consistent with this result, most H3K9 demethylases, including JMJD1A/B/C and JMJD2B/C, have been shown to be required for efficient somatic cell reprogramming. In line with our results, [@bib54] showed that *Jmjd1c* KD reduced somatic cell reprogramming efficiency. However, [@bib6] showed that *Jmjd1c* KD in pre-iPSCs did not obviously affect vitamin C-induced further reprogramming. Their failure to detect JMJD1C\'s role in reprogramming could be explained as follows. First, they generated iPSCs in a medium containing vitamin C; different culture conditions may give rise to different results. Second, the conversion from pre-iPSCs to fully reprogrammed iPSCs represents the late stage of the reprogramming; the function of JMJD1C could not be detected if it would act in earlier stages of pluripotency induction.

The mechanism underlying the function of H3K9 demethylases in reprogramming remains largely unknown. JMJD1C was shown to induce endogenous *Oct4* expression during reprograming of fibroblasts to pluripotency ([@bib54]). Here, we show that JMJD1C ensures efficient somatic cell reprogramming, at least in part, by regulating *miR-200* family expression, providing a potential mechanistic explanation. This notion is also supported by the previous study that *miR-200* family is critical for MET and iPSC generation ([@bib23], [@bib62]). Moreover, characterization of WT and *Jmjd1c* KO iPSCs reveals that normal expression of JMJD1C is critical for the full activation of endogenous pluripotency genes and efficient silencing of exogenously introduced pluripotency genes. Therefore, this study provides crucial insights into how JMJD1C functions in maintaining ESC self-renewal and during somatic cell reprogramming.

Despite critical roles of JMJD1C in pluripotency regulation, *Jmjd1c* KO mice are viable ([@bib30]). The JMJD1/KDM3 family has three members (JMJD1A/KDM3A, JMJD1B/KDM3B, and JMJD1C/KDM3C), which may have functional redundancy *in vivo*. In the absence of *Jmjd1c*, other family members may compensate its deficiency during embryonic development. Similar to JMJD1C, both JMJD1A and JMJD2C have been demonstrated to be required for ESC self-renewal ([@bib11], [@bib41]). However, both *Jmjd1a* and *Jmjd2c* KO mice are also viable ([@bib25], [@bib48], [@bib60]), suggesting the possibility of redundancy for the JMJD1/KDM3 family *in vivo*.

In addition, studies have suggested that the expression of JMJD1C associates with normal development such as spermatogenesis ([@bib30], [@bib45]), circulating vascular endothelial growth factor levels ([@bib9]), and concentrations of liver enzymes ([@bib5]), and that its dysfunction results in various diseases such as leukemia ([@bib7], [@bib55], [@bib68]), intracranial germ cell tumors ([@bib63], [@bib64]), and Rett syndrome ([@bib52]). Because the majority of these results were obtained from genome-wide association studies, the underlying mechanisms remain largely unknown. MicroRNAs of the *miR-200* family play critical roles in the EMT process and development of cancers such as ovarian, breast, and prostate cancer ([@bib16]). Discovery of the regulatory role for JMJD1C over the transcription of the *miR-200* family opens new angles for the study of *Jmjd1c* deficiency-associated diseases and possible strategies for their treatment.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Mouse ESC lines (all experiments were performed in J1 ESC lines, unless indicated otherwise), MEFs, Plat-E cells, and HEK 293FT cells were cultured in the defined medium as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Lentiviral Production and RNAi Screen {#sec4.2}
-------------------------------------

Four different shRNAs were used for each H3K9 demethylase. Non-target shRNA (shNT) and shLuciferase (sh*Luc*) were used as negative controls, and shRNAs against *Oct4* and *Nanog* were used as positive controls. Viral particles for shRNAs were produced in 293FT cells. A detailed protocol of lentiviral production and infection of ESCs is available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. The shRNA sequences used in this study are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

RNA Isolation, Reverse Transcription, and Real-Time qPCR {#sec4.3}
--------------------------------------------------------

Total RNA was isolated using the TRIzol Reagent (Invitrogen). Detailed procedures are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. The primers are listed in the [Table S3](#mmc2){ref-type="supplementary-material"}.

Competition Assays {#sec4.4}
------------------

Competition assays of ESCs were performed according to the protocol developed by the Ihor R Lemischka laboratory ([@bib33]). In brief, 80% shRNA-expressing ESCs (GFP^+^ from shRNA-pLKO.pig) were mixed with 20% control shRNA-expressing ESCs (GFP^−^ from sh*Luc*-pLKO.1), and cultured under standard ESC self-renewal conditions. After six passages (12 days), FACS analysis was performed to determine the percentage of GFP^+^ cells. The percentage of GFP^+^ cells should remain ∼80% if an shRNA does not affect ESC self-renewal.

Colony-Formation Assays {#sec4.5}
-----------------------

Colony-formation assays were conducted as previously described ([@bib1]). In brief, *Jmjd1c* or control shRNAs were introduced into J1 ESCs by lentivirus-mediated infection. Three days later, cells were trypsinized and seeded at a density of 2,000 cells per 6-cm dish to form ESC colonies. After 7 days, colonies were stained using the VECTOR Blue Alkaline Phosphatase Substrate Kit (Vector Laboratories) and counted.

Chromatin Immunoprecipitation Assays {#sec4.6}
------------------------------------

ChIP assays were carried out as previously described with some modifications ([@bib36]). Detailed procedures are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. The primers for ChIP-qPCR are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

Somatic Cell Reprogramming {#sec4.7}
--------------------------

Somatic cell reprogramming was induced as previously described ([@bib57]). Detailed procedures are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Microarray Analysis {#sec4.8}
-------------------

Microarray was carried out with the Affymetrix GeneChip Mouse Genome 430 2.0 Arrays. Detailed procedures are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.9}
--------------------

Data are presented as the mean ± SD and analyzed by the unpaired Student\'s t test. p Values of ≤0.05 were considered statistically significant.
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